CRISPR, an innovation in the field of gene editing. Proposing a way to include it in a public health system


Published: Sep 25, 2020
Keywords:
gene editing gene therapy distributive justice
Nikolaos Kolisis (Νικόλαος Κολίσης)
Abstract

The invention of CRISPR technology and its current and potential applications have been a subject of controversy among scientists, philosophers and legal theorists. After taking under consideration the current discussion concerning the use of CRISPR for editing human genome the article treats the question of a wider offer of CRISPR-based therapies from a Public Healthcare system and proposes method for a fair and financially sustainable way for adopting the new possibilities this new tool has to offer.

Article Details
  • Section
  • Original Articles
Downloads
Download data is not yet available.
References
Atlan, H. La fin du tout génétique: Vers de nouveaux paradigmes en biologie: Editions Quæ, Versailles, France, 1999.
Baylis F. Altered Inheritance: CRISPR and the Ethics of Human Genome Editing, Harvard University Press 2019.
Buchanan, A. Human Nature and Enhancement. 2009 Bioethics 23: 141-50.
Cwik B. Moving Beyond 'Therapy' and 'Enhancement' in the Ethics of Gene Editing. Camb Q Health Ethics, 2019 28: 695-707.
D’Amato, A. Do we owe a Duty to Future Generations to Preserve the Global Environment? American Journal of International Law, 84(1) 1990, 190-198.
Davies K. Walk the Line: Debating a Germline Editing Moratorium. The CRISPR Journal, 2 2019: 74-76.
Gyngell, C. and Douglas, T. Selecting Against Disability: The Liberal Eugenic Challenge and the Argument from Cognitive Diversity. J Appl Philos, 2018, 35: 319-340.
Kass L.R. Making Babies-the New Biology and the Old Morality. Public Interest, 1972 26: 18-56
Lanphier E., Urnov F., Haecker S.E., et al. Don’t edit the human germ line. Nature, 2015, 519:410-411.
Liang P., Xu Y., Zhang X., et al. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell, 2015,6: 363-372.
National Academies of Sciences, Engineering, Medicine. Human Genome Editing: Science, Ethics, and Governance. Washington, DC: National Academies Press.
National Academies of Sciences, Engineering. 2019. Second International Summit on Human Genome Editing: Continuing the Global Discussion: Proceedings of a Workshop In Brief: National Academies Press Washington, DC, 2017.
Nestor M.W., Wilson R.L. Can the Use of CRISPR in Humans Result in Decreased Social Justice for Future Stakeholders?” Ethics BiolEng Med 2018, 9: 5-16.
Parens E. Should We Hold the (Germ) Line? J Law Med Ethics, 1995, 23: 173-76.
Parfit, D. Future People, the Non‐Identity Problem, and Person‐Affecting Principles. Philosophy & Public Affairs, 2017, 45: 118-157.
Scanlon, Τ.Μ. WhyDoes Inequality Matter? Oxford University Press, 2018.
The Nuffield Council on Bioethics. Genome editing and human reproduction: social and ethical issues. 2018. https://www.nuffieldbioethics.org/publications/genome-editing-and-human-reproduction.
Ünal M., Unal D. Gene Doping in Sports. Sports medicine Auckland, N.Z., 2004 34: 357-62.
Van Dijke I., Bosch L., Bredenoord A., et al. The ethics of clinical applications of germline genome modification: a systematic review of reasons. Hum Reprod, 2018, 33: 1777-1796.
Wilson RC, Carroll D. The Daunting Economics of Therapeutic Genome Editing. The CRISPR Journal, 2019, 2:280-284.
Ευρωπαϊκή Σύμβαση για τη Βιοϊατρική (Σύμβαση Οβιέδο) (σχετικά με παρεμβάσεις σε έμβρυα και γενικά στο ανθρώπινο γονιδίωμα, ιδίως άρθρα 5, 6, 10, 18, 21, 22).